

Infection Prevention and Control for Tuberculosis

**A.Willem Sturm, MD, PhD
Provincial Department of Health
KwaZulu-Natal
South Africa**

Loss of fitness, 1953

- **Middlebrook, G., and M. L. Cohn**

-

“Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli”

(Science, 1953, 118:297-299)

Regaining fitness


- **Compensatory mutations**
 - **? Other mechanisms**
- 
- The diagram consists of several elements: a list of mechanisms at the top left, a bracket on the right grouping them, a line extending from the bracket to the right, a horizontal line below it, an arrow pointing left from the end of that line to the text 'highly successful resistant strains', a vertical arrow pointing down from that text to a second list of specific strains, and a bracket on the right of the second list pointing to the text '? over-compensation'.

**highly successful
resistant strains**

- **Beijing**
- **F28**
- **F16/LAM4/KZN**

**? over-
compen-
sation**


Competition in mice: fitness test



□ V9124 (S)
 ■ V2475 (M)
 ▨ TF275 (X)

(B)

Wilcoxon Signed Rank Test for the two strains competition		
Group Comparison	Organs	P-value
Sens versus MDR	Lung	0.0996
Sens versus MDR	Spleen	0.0059
MDR versus XDR	Lung	0.0645
MDR versus XDR	Spleen	0.0020
Sens versus XDR	Lung	0.6758
Sens versus XDR	Spleen	0.0371




□ V9124 (S)
 ■ V2475 (M)
 ▨ TF275 (X)

(D)


Wilcoxon Signed Rank Test for three strains competition		
Group Comparison	Organs	P-value
Sens versus MDR	Lung	0.9097
Sens versus MDR	Spleen	0.0269
MDR versus XDR	Lung	0.4697
MDR versus XDR	Spleen	0.0122
Sens versus XDR	Lung	1.0000
Sens versus XDR	Spleen	0.0068

(collaborative project with Duke University, Sunhee Lee et al)

Cytotoxicity of F15/LAM4/KZN isolates on alveolar epithelium



Bacterial burden of F15/LAM4/KZN in lung and spleen and lung pathology



(collaborative project with Duke University, Sunhee Lee et al)

**Virulent (fit), resistant
M. tuberculosis strains
are a reality !**

How do we deal with that ?

TB control = prevention of transmission

- **Decreasing infectiousness of patients**
- **Prevention of transmission**
 - **infection prevention in health care facilities**
 - **infection prevention in public transport and buildings**
 - **infection prevention at home**
- **Prophylaxis for the non-infected**
 - **vaccination**
 - **prophylactic medication**

TB control = prevention of transmission

- **Decreasing infectiousness of patients**
- **Prevention of transmission**
 - infection prevention in health care facilities
 - infection prevention in public transport and buildings
 - infection prevention at home
- **Prophylaxis for the non-infected part of the population**
 - vaccination
 - prophylactic medication

XDR in KZN = TDR

isoniazid	R
rifampicin	R
pyrazinamide	R
ethambutol	R
streptomycin	R
ethionamide	R
ofloxacin	R
moxifloxacin	R
kanamycin	R
amikacin	R
capreomycin	R
PAS	S
linezolid	S
meropenem/clavulanic acid	S

Different epidemics per geographical region

- **Western Cape province**
 - **MDR transmitted**
 - **XDR not transmitted**
- **KwaZulu-Natal**
 - **MDR transmitted (Beijing, F28 and F15/LAM4/KZN)**
 - **XDR transmitted: F15/LAM4/KZN only**

TB control = prevention of transmission

- **Decreasing infectiousness of patients**
- **Prevention of transmission**
 - **infection prevention in health care facilities**
 - **infection prevention in public transport and buildings**
 - **infection prevention at home**
- **Prophylaxis for the non-infected**
 - **vaccination**
 - **prophylactic medication**

Prevention of transmission in health care facilities

- **Administrative control**
 - triage
- **Environmental control**
 - ventilation
 - airflow control
- **Personal protection**
 - masks/respirators



**Where is
the
problem ?**


Risk assessment in specialised TB facilities in KZN

IPC unit

KZN Department of Health

Challenges with triage

- **At which point in the patient flow?**
- **What to do with (many) coughing patients?**



over-crowding in OPD ← **where?** ←

Challenges with environmental control

- **Building structure**
 - ventilation systems
 - ceiling height
 - isolation wards
- **Overcrowding**
 - ward
 - OPD
- **Cough areas/booths**













Challenges with personal protection

- **Adherence**
 - unpleasant for user
 - unfriendly for patients
- **Confusing information**
 - when to discard ?

Filter efficiency

- **Particle capture efficiency of electret (charged) filters decreases with filter load**
- **Maximum filter load for N series masks ≥ 200 mg**

└─→ **efficiency insufficient**

└─→ **bacteria first**

Challenges with personal protection

- **Adherence**
 - unpleasant for user
 - unfriendly for patients
- **Confusing information**
 - when to discard ?
- **Fit-testing**
 - consistency in donning the mask
 - procurement system

Risk assessment in specialised TB facilities in KZN

- **All 8 facilities had major challenges in all areas**
- **Need for structural changes in OPDs/clinics and wards**
 - **no short term solutions**
 - **maximise ventilation systems**
- **Need for optimisation of personal protection**

TB control = prevention of transmission

- **Decreasing infectiousness of patients**
- **Prevention of transmission**
 - **infection prevention in health care facilities**
 - **infection prevention in public transport and buildings**
 - **infection prevention at home**
- **Prophylaxis for the non-infected part of the population**
 - **vaccination**
 - **prophylactic medication**

Infection prevention outside health care facilities

- **Community education**
 - **household education/counseling**
 - **targeted group education**

TB control = prevention of transmission

- **Decreasing infectiousness of patients**
- **Prevention of transmission**
 - **infection prevention in health care facilities**
 - **infection prevention in public transport and buildings**
 - **infection prevention at home**
- **Prophylaxis for the non-infected part of the population**
 - **vaccination**
 - **prophylactic medication**

INH resistance in culture confirmed cases in KZN

1 Jan 2006 – 30 June 2007

n=25537

	No. of patients	%
All	6543	25.6
Single INH resistant	807	3.2
MDR	5377	21
pre-XDR	9	
XDR	610	2.4
others	1785	7


Botswana IPT trial

- **INH resistance in those receiving 36 mths IPT: 14%**
- **Background INH resistance: 9 %**
- **Increase: 5 % (55% in 3 years)**

Extrapolation of Botswana results to KZN

	Background resistance	Resistance after 3 years IPT
Botswana	9 %	14 %
KZN	26 %	40.3%

Public health responsibility



Should we introduce IPT everywhere or allow for differential approach ?

Back to basics

- **The current epidemic in KZN is the result of:**
 - **a high density of TB transmitters in the population**
 - **a high density of highly TB susceptible individuals in the population (the HIV infected)**

Back to basics

- **We need to decrease both these groups of individuals !**
- **How?**
 - **Active, early case finding**
 - **before patients become infectious**
 - **before a productive cough develops**
 - **Early ARV treatment**
 - **before the CD4 count starts dropping**
 - **immediately on diagnosis (active case finding)**

Acknowledgements

- **The IPC team**
 - **Prashini Moodley**
 - **Jessica Thompson**
 - **Alcino Pillay**
 - **Loshni Ganas**
 - **Lab. technologists**
- **The scientific team**
 - **Prashini Moodley**
 - **Bisi Ashiru**
 - **Sunshhee Lee**
 - **William Jacobs Jr**
 - **Masters students**

Thank you